| Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164 DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Journal of Clinical Oncology 38 (1), 11, 2020 | 781 | 2020 |
| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer J Tie, JD Cohen, K Lahouel, SN Lo, Y Wang, S Kosmider, R Wong, ... New England Journal of Medicine 386 (24), 2261-2272, 2022 | 414 | 2022 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 369 | 2017 |
| Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study J Tie, JD Cohen, Y Wang, L Li, M Christie, K Simons, H Elsaleh, ... Gut 68 (4), 663-671, 2019 | 279 | 2019 |
| Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer B Lee, L Lipton, J Cohen, J Tie, AA Javed, L Li, D Goldstein, M Burge, ... Annals of Oncology 30 (9), 1472-1478, 2019 | 162 | 2019 |
| Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study J Tie, Y Wang, J Cohen, L Li, W Hong, M Christie, HL Wong, S Kosmider, ... PLoS medicine 18 (5), e1003620, 2021 | 108 | 2021 |
| Effects of a structured exercise program on physical activity and fitness in colon cancer survivors: one year feasibility results from the CHALLENGE trial KS Courneya, JL Vardy, CJ O'Callaghan, CM Friedenreich, KL Campbell, ... Cancer Epidemiology, Biomarkers & Prevention 25 (6), 969-977, 2016 | 99 | 2016 |
| KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. DT Le, P Kavan, TW Kim, ME Burge, E Van Cutsem, H Hara, PMK Boland, ... Journal of Clinical Oncology 36 (15_suppl), 3514-3514, 2018 | 95 | 2018 |
| RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis CE Bond, DM McKeone, M Kalimutho, ML Bettington, SA Pearson, ... Oncotarget 7 (43), 70589, 2016 | 92 | 2016 |
| Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies J Tie, JD Cohen, SN Lo, Y Wang, L Li, M Christie, M Lee, R Wong, ... International journal of cancer 148 (4), 1014-1026, 2021 | 81 | 2021 |
| Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness DT Lincoln, F Al-Yatama, FMA Mohammed, AG Al-Banaw, M Al-Bader, ... Anticancer research 30 (3), 767-775, 2010 | 78 | 2010 |
| Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy … P Gibbs, V Heinemann, NK Sharma, J Taieb, J Ricke, M Peeters, ... Clinical colorectal cancer 17 (4), e617-e629, 2018 | 67 | 2018 |
| Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type … AG Hill, MP Findlay, ME Burge, C Jackson, PG Alfonso, L Samuel, ... Clinical Cancer Research 24 (10), 2276-2284, 2018 | 55 | 2018 |
| Targeted therapy for metastatic colorectal cancer TJ Price, M Tang, P Gibbs, DG Haller, M Peeters, D Arnold, E Segelov, ... Expert review of anticancer therapy 18 (10), 991-1006, 2018 | 53 | 2018 |
| Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal … AP Barbour, ET Walpole, GT Mai, EH Barnes, DI Watson, SP Ackland, ... Annals of Oncology 31 (2), 236-245, 2020 | 45 | 2020 |
| Adjuvant nab-paclitaxel+ gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial MA Tempero, U Pelzer, EM O'Reilly, J Winter, DY Oh, CP Li, G Tortora, ... Journal of Clinical Oncology 41 (11), 2007, 2023 | 44 | 2023 |
| Current opinion on optimal treatment for colorectal cancer TJ Price, E Segelov, M Burge, DG Haller, SP Ackland, NC Tebbutt, ... Expert review of anticancer therapy 13 (5), 597-611, 2013 | 41 | 2013 |
| Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent JD Lickliter, AB Francesconi, G Smith, M Burge, A Coulthard, S Rose, ... British Journal of Cancer 103 (5), 597-606, 2010 | 34 | 2010 |
| Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study R Shapira-Frommer, L Mileshkin, L Manzyuk, N Penel, M Burge, ... Gynecologic oncology 166 (2), 211-218, 2022 | 28 | 2022 |
| A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non‐contrast CT scanning on the management of operable pancreatic and peri … ME Burge, N O'Rourke, D Cavallucci, R Bryant, A Francesconi, K Houston, ... HPB 17 (7), 624-631, 2015 | 27 | 2015 |
david wyldDirector Medical Oncology Royal Brisbane and Womens HospitalVerified email at health.qld.gov.au
